| Report ID | 277216 |
| Drug Identification Number | 02083523 |
| Brand name | BEZALIP SR |
| Common or Proper name | BEZAFIBRATE 400 MG |
| Company Name | ALLERGAN INC |
| Market Status | MARKETED |
| Active Ingredient(s) | BEZAFIBRATE |
| Strength(s) | 400MG |
| Dosage form(s) | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL ORAL |
| Packaging size | 30 TABLETS |
| Anatomical Therapeutical Chemical (ATC) code | C10AB |
| Anatomical Therapeutical Chemical (ATC) description | LIPID MODIFYING AGENTS, PLAIN |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2027-03-31 |
| Actual discontinuation date | |
| Remaining supply date | |
| Discontinuation status | To be discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | Last estimated sale date of 31 Mar 2027 |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | Company contact information; Telephone number: 800-668-6424 Email address: [email protected] Website address: allergan.ca Postal address: 500-85 Enterprise Blvd, Markham, Ontario, L6G 0B5 |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v3 | 2026-02-03 | French | Compare |
| v2 | 2026-02-03 | English | Compare |
| v1 | 2026-02-03 | English | Compare |
Showing 1 to 3 of 3